Evidence map›Paper›PMID 41852800›Full record

ArticleHealth affairs scholar2026

A multi-stakeholder survey on communicating cost-effectiveness uncertainties to stakeholders: a case study of ICER.

Jan-Willem Versteeg, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Daniel Ollendorf, Christine Leopold

Abstract read
In one paragraph

Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jan-Willem VersteegDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID https://orcid.org/0000-0002-1880-6171
Wim G GoettschDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID https://orcid.org/0000-0002-8022-7496
Aukje K Mantel-TeeuwisseDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID https://orcid.org/0000-0002-8782-0698
Daniel OllendorfCenter for Evaluation of Value and Risk in Health, Tufts Medical Center, Boston MA 02111, United States.ORCID https://orcid.org/0000-0001-6016-8129
Christine LeopoldDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID https://orcid.org/0000-0002-2046-8490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cost-effectiveness analyses (CEA) are integral to health technology assessments performed by the US-based Institute for Clinical and Economic Review (ICER). This study aims to examine how stakeholder groups perceive and interpret ICER's communication on uncertainty in CEA findings. Methods: We performed a multi-stakeholder survey among individuals recruited via ICER's weekly update email (March/April 2025). The survey focused on 6 topics related to ICER's uncertainty communication based on the organization's published reference case, consisting of Likert-scale and open-ended questions. Results were analyzed descriptively with thematic analysis of open-ended responses. Results: Thirty-four responses were collected, representing different stakeholder groups. Results indicated that 16/18 of respondents found sensitivity analyses to be communicated clearly (varying by analysis type), while 9/17 found structural and parametric assumptions to be communicated clearly. Most report sections were understandable respondents, and 15/23 found the communication of uncertainty outside reports to be understandable. Thematic analysis identified scenario analyses, structural/parametric uncertainty communication, and stakeholder-tailored communications as areas for future enhancement. Conclusions: While methodological guidelines focus on quantifying uncertainty, limited guidance exists for communicating key facts on uncertainty to different stakeholder groups. This study highlights specific stakeholder-perceived areas for improvement. Future research could compare these results to other organizations.

Indexed as

cost-effectiveness analysishealth technology assessmentuncertaintyuncertainty communication

Identifiers

PMID41852800
PMCPMC12993711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.